The great escape: Improving the activity of chemotherapeutics delivered by antibody-drug conjugates with integrated endosome escape and nuclear-directional trafficking control capabilies

伟大的逃亡：通过具有整合的内体逃逸和核定向运输控制能力的抗体-药物偶联物来提高化疗药物的活性

• 批准号: 358262
• 负责人: Leyton Jeffrey V
• 金额: $ 41.16万
• 依托单位: Universit de Sherbrooke
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-10-01 至 2021-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=358262&lang=en
• 关键词: Antibody-Drug Conjugates; Drug Intracellular Accumulation; Nuclear Routing And Accumulation; Pet Imaging In Drug Development; Selective Endosome Escape; Targeted Chemotherapy

The image of the 'therapeutic missile' commonly used to present targeted drug delivery agents emphasizes precision, control, and efficiency. For the next evolution of cancer treatment, antibody-drug conjugates (ADCs) are a great representative of this con

通常用于展示靶向药物递送剂的“治疗导弹”的图像强调精度、控制和效率。对于癌症治疗的下一个发展，抗体-药物偶联物（adc）是这方面的一个很好的代表